Výsledky vyhledávání - "Lars Muehlenhoff"

Akademický článek

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Autor: Wolfgang Schuette, Peter Schirmacher, Wilfried E. E. Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)

Abstract Background We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). Methods REASON (NCT00997230) was a non-interventional study

Externí odkaz: https://doaj.org/article/cac53fc992d244659adde34115d80827

Zobrazit plný text záznamu

Plný text ve formátu HTML

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Autor: Ute Zirrgiebel, Manfred Dietel, Wolfgang Schuette, Michael Thomas, Lars Muehlenhoff, Peter Schirmacher, Wilfried Eberhardt

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer

Background We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). Methods REASON (NCT00997230) was a non-interventional study in German

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a411bd53798b725506f1f6c5eeb0b99f
http://archiv.ub.uni-heidelberg.de/volltextserver/24283/

Zobrazit plný text záznamu

Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial

Autor: Ute Zirrgiebel, Manfred Dietel, Timo Behlendorf, Peter Schirmacher, Wilfried Eberhardt, Lars Muehlenhoff, Michael Thomas, Wolfgang Schuette

Publikováno v: Journal of Clinical Oncology. 33:e19001-e19001

e19001 Background: Somatic mutations in the EGFR kinase domain strongly correlate with increased response to EGFR TKIs in NSCLC, yet limited information exists about EGFR mutations of all 4 exons i...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa1eab9249d82f9343fdf1b5e4a9d078
https://doi.org/10.1200/jco.2015.33.15_suppl.e19001

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání